- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Acurx Pharmaceuticals LLC (ACXP)
Acurx Pharmaceuticals LLC stock price live, this page displays NASDAQ ACXP stock exchange data. View the ACXP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Acurx Pharmaceuticals LLC real time stock price chart below.
What Is the Acurx Pharmaceuticals LLC Stock Price Today?
The Acurx Pharmaceuticals LLC stock price today is 4.480.
What Is the Stock Symbol for Acurx Pharmaceuticals LLC?
The stock symbol for Acurx Pharmaceuticals LLC is ""ACXP.""
What Stock Exchange Does Acurx Pharmaceuticals LLC Trade On?
Acurx Pharmaceuticals LLC is listed and trades on the NASDAQ stock exchange.
Is Acurx Pharmaceuticals LLC a Good Stock to Buy?
Determining whether Acurx Pharmaceuticals LLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACXP quote. (ISIN: US00510M2035)
What Is the Acurx Pharmaceuticals LLC Stock Price Today?
The Acurx Pharmaceuticals LLC stock price today is 4.480.
What Is the Stock Symbol for Acurx Pharmaceuticals LLC?
The stock symbol for Acurx Pharmaceuticals LLC is ""ACXP.""
What Stock Exchange Does Acurx Pharmaceuticals LLC Trade On?
Acurx Pharmaceuticals LLC is listed and trades on the NASDAQ stock exchange.
Is Acurx Pharmaceuticals LLC a Good Stock to Buy?
Determining whether Acurx Pharmaceuticals LLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACXP quote. (ISIN: US00510M2035)
NASDAQ
Currency in USD
4.480
+0.010(+0.22%)
Closed·
After Hours
4.470-0.010(-0.22%)
·
Fair Value
An estimate of a Acurx Pharmaceuticals LLC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.420
4.595
52 wk Range
4.170
47.800
ACXP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
1/2
Fair Value
An estimate of a Acurx Pharmaceuticals LLC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.4204.595
52 wk Range
4.17047.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ACXP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Acurx Pharmaceuticals LLC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
113.950
Upside
+2,443.53%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
- Form 8K Acurx Pharmaceuticals LLC For: 17 July
- Investing.com
- Form 8K Acurx Pharmaceuticals LLC For: 17 July
- Investing.com
- Form 8K Acurx Pharmaceuticals LLC For: 20 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Acurx Pharmaceuticals LLC Company Profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals LLC Earnings Call Summary for Q1/2025
- Acurx Pharmaceuticals reported Q1 2025 EPS of -$0.11, beating forecast of -$0.38; stock declined 6.33% pre-market to $0.37
- Net loss reduced to $2.1 million from $4.4 million in Q4 2024; cash position improved to $4.6 million from $3.7 million
- Company highlighted cost reductions and progress in antibiotic development, particularly ibezafolstat for C. Difficile Infection treatment
- Management focuses on securing funding for Phase III trials; EPS forecasts suggest further narrowing of losses in upcoming quarters
- Key challenges include funding needs, regulatory hurdles, and market competition in CDI treatment space
Last Updated: 13/05/2025, 13:48
Read Full TranscriptCompare ACXP to Peers and Sector
Metrics to compare | ACXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACXPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −3.1x | −0.5x | |
PEG Ratio | −0.01 | −0.06 | 0.00 | |
Price/Book | 3.0x | 1.7x | 2.6x | |
Price / LTM Sales | - | 106.6x | 3.3x | |
Upside (Analyst Target) | - | 219.3% | 42.9% | |
Fair Value Upside | Unlock | 10.7% | 6.2% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 113.950
(+2,443.53% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.11 / -0.38
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Acurx Pharmaceuticals LLC Trade On?
Acurx Pharmaceuticals LLC is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Acurx Pharmaceuticals LLC?
The stock symbol for Acurx Pharmaceuticals LLC is "ACXP."
What Is the Acurx Pharmaceuticals LLC Market Cap?
As of today, Acurx Pharmaceuticals LLC market cap is 6.89M.
What Is Acurx Pharmaceuticals LLC's Earnings Per Share (TTM)?
The Acurx Pharmaceuticals LLC EPS (TTM) is -13.72.
When Is the Next Acurx Pharmaceuticals LLC Earnings Date?
Acurx Pharmaceuticals LLC will release its next earnings report on 11 Aug 2025.
From a Technical Analysis Perspective, Is ACXP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Acurx Pharmaceuticals LLC Stock Split?
Acurx Pharmaceuticals LLC has split 1 times.
How Many Employees Does Acurx Pharmaceuticals LLC Have?
Acurx Pharmaceuticals LLC has 4 employees.
What is the current trading status of Acurx Pharmaceuticals LLC (ACXP)?
As of 12 Aug 2025, Acurx Pharmaceuticals LLC (ACXP) is trading at a price of 4.48, with a previous close of 4.47. The stock has fluctuated within a day range of 4.42 to 4.60, while its 52-week range spans from 4.17 to 47.80.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.